GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading,
GSK lifts long-term sales targets on new drug pipeline
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
GSK plans £2 billion share buyback, boosts long-term outlook
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its drug pipeline. Read more at The Business Times.
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK sees FY25 core EPS growth 6%-8%
GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...
FierceBiotech2h
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK boosts 2031 revenue target to over £40bn following robust Q4 results
The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth ...
GSK expects to achieve sales of over GBP 40B by 2031
The company said, “By 2031, GSK (GSK) now expects to achieve sales of more than GBP 40B, previously greater than GBP 38B, on a risk-adjusted ...
London midday: Stocks slightly higher; GSK jumps on guidance upgrade
London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...
GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...